Tenaya Therapeutics(NASDAQ) TNYA

Market Cap$126.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-96%
5 Year-98%
1 Year-65%
1 Month-17%
$0.56
+0.00%
+0.00Today
Tenaya Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.562026-10-05
Tenaya Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.36%USD 0.592026-09-28
1 month-17.43%USD 0.682026-09-04
3 month-38.68%USD 0.922026-07-07
Year to date-20.72%USD 0.712025-12-31
1 year-65.18%USD 1.622025-10-03
3 year-78.05%USD 2.572023-10-06
5 year-97.66%USD 24.122021-10-06
Since inception-96.33%USD 15.352021-07-30

Tenaya Therapeutics Financials at a Glance

Market Cap

$126.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.34

Net Income (TTM)

-$103.12

EPS (TTM)

-$0.53

P/E Ratio

-1.07

Dividend

$0.00

Beta (Volatility)

2.01 (High)

Price

$0.56

Volume

2,868,032.153

Open

$0.57

Previous Close

$0.56

Daily Range

$0.55 - $0.58

52-Week Range

$0.53 - $2.35

Estimated Earnings Date

N/A

TNYA News

Foolcom-Featured.png

Tenaya (TNYA) Q2 Loss Narrows 59%

Motley Fool Markets TeamAug 7, 2025
wooden cube blocks

Why This Nasdaq Stock Caught Fire This Week

George Budwell, PhDApr 20, 2023

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tenaya Therapeutics

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. It operates through its product platforms: gene therapy, cellular regeneration, and precision medicine. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Olson in August 2016 and is headquartered in South San Francisco, CA.

Industry

Biotechnology

Sector

Health Care

Employees

70

CEO

Faraz Ali, MBA

Website

www.tenayatherapeutics.com

TNYA Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-121.86%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-93.46%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$126.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

224.23M

Volume

2.87M

Avg. Volume

2.39M

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Tenaya Therapeutics Performance Analysis

Tenaya Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Tenaya Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.7656.6%
20232023-12-31USD -1.68-39.0%
20242024-12-31USD -1.31-22.1%
20252025-12-31USD -0.59-54.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.11

N/A

Gross Profit

-$0.59

+0.3%

Gross Margin

-52.97%

N/A

Market Cap

$126.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.29

N/A

Employees

70

N/A

Net Income

-$43.39

+1.9%

EBITDA

-$19.20

+0.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$82.03

+9.6%

Total Debt

$3.95

+0.3%

Accounts Receivable

$0.37

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.07

+0.1%

Short Term Debt

$2.88

+1.0%

Return on Assets

-95.61%

+1.4%

Return on Invested Capital

-66.78%

+1.5%

Free Cash Flow

-$3.71

+0.2%

Operating Cash Flow

-$3.55

+0.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,777.74+0.01%
^DJIDJI
$51,304.21+0.00%
^IXICNASDAQ
$27,461.27+0.01%
BTCBitcoin
$85,510.00+0.00%

Questions About TNYA

What is the current price of Tenaya Therapeutics?

Tenaya Therapeutics is trading at $0.56 per share.

What is the 52-week range for Tenaya Therapeutics?

Over the past 52 weeks, Tenaya Therapeutics has traded between $0.53 and $2.35.

How much debt does Tenaya Therapeutics have?

As of the most recent reporting period, Tenaya Therapeutics reported total debt of $3.95M.

How much cash does Tenaya Therapeutics have on hand?

Tenaya Therapeutics reported $78.09M in cash and cash equivalents in its most recent financial results.

What is Tenaya Therapeutics’s dividend yield?

Tenaya Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services